Table 1.
Participant characteristics at baseline in 1992–1993 by IL-6 values
| Participant Characteristic | IL-6 Q123 | IL-6 Q4 |
|---|---|---|
| Demographics | ||
| Age, years, mean (SD) | 74.6 ± 5.2 | 75.6 ± 5.6 † |
| Male sex, n (%) | 1285 (39.6) | 523 (48.3) † |
| Black race, n (%) | 549 (16.9) | 217 (20.0) ‡ |
| Alcohol use, drinks per week, n (%) | 1.95 ± 5.0 | 2.5 ± 9.0 ‡ |
| 0 | 1790 (55.2) | 610 (56.5) |
| 1–7 | 1113 (34.3) | 363 (33.6) |
| >7 | 340 (10.5) | 107 (9.9) |
| Smoking status | ||
| Current | 284 (8.9) | 141 (13.2) |
| Past | 1374 (43.2) | 515 (48.4) |
| Never | 1526 (47.9) | 409 (38.4) |
| BMI, kg/m2, mean (SD) | 26.5 ± 4.4 | 27.9 ± 5.6 † |
| Medical History, n (%) | ||
| Diabetes | 424 (13.1) | 243 (22.5) † |
| Coronary heart disease | 631 (19.4) | 312 (28.8) † |
| Heart failure | 132 (4.1) | 129 (11.9) † |
| Medications, current use, n (%) | ||
| Thiazides | 519 (16.0) | 211 (19.5) ‡ |
| Oral estrogens* | 283 (14.4) | 55 (9.8) ‡ |
| Thyroid medications | 334 (10.3) | 98 (9.0) |
| Psychotropics | 38 (1.2) | 52 (4.8) † |
| Oral corticosteroids | 319 (9.8) | 109 (10.1) |
| Osteoporosis medications | 651 (20.0) | 138 (12.7) † |
| Any fall in the past year, n (%) | 490 (15.1) | 199 (18.5) ‡ |
| Self-rated good health, n (%) | 2623 (80.8) | 790 (73.1) † |
| 15 foot walk time, seconds, mean (SD) | 5.4 ± 2.0 | 6.0 ± 4.0 † |
| IADL impairment, n (%) | 268 (8.3) | 168 (15.6) † |
| Depression score, CES-D, mean (SD) | 5.2 ± 4.8 | 6.1 ± 5.1 † |
| Cognitive score, 3MSE, mean (SD) | 90.5 ± 9.3 | 88.4 ±11.3 † |
| Laboratory Measures, mean (SD) | ||
| Glucose, mg/dL | 106.5 ± 34.7 | 113.8 ± 37.7 † |
| Serum eGFRcys, mL/min/1.73 m2 | 72.1 ± 18.0 | 69.3 ± 20.5 † |
| Serum albumin, g/dL | 3.9 ± 0.3 | 3.9 ± 0.3 † |
†
p < 0.001;
‡
p < 0.05;
*
Reported for women only (n=2519);
BMI = body mass index; IADL = instrumental activities of daily living; 3MSE = modified mini-mental state exam; SBP=systolic blood pressure; DBP=diastolic blood pressure; eGFRcys = serum cystatin derived estimated glomerular filtration rate.